Cancer remains a devastating disease, but scientific progress provides hope. Over the past 20 years, innovative therapies, along with early detection and reduced tobacco use, have contributed to a drop in cancer deaths across the United States, sparing the lives of 1.5 million Americans.1
Astellas Oncology is collaborating with other industry leaders to ensure these trends continue. We focus on discovering and developing treatments to address the unmet needs of cancer patients who are facing one of the most challenging health issues of their lives.
Prostate cancer is the most commonly diagnosed cancer in American men and the second-leading cause of cancer-related deaths among this group.2 More than 230,000 men will be diagnosed with prostate cancer this year.
Most prostate cancers are diagnosed when the disease is confined to the prostate and nearby organs, and overall prostate cancer five-year survival is 99 percent. But according to one study, five-year survival drops to 28 percent in men diagnosed with prostate cancer that has spread to other parts of the body.1
Lung cancer kills more men and women than any other cancer type and symptoms of lung cancer do not usually occur until the cancer is advanced. More than 220,000 people will be diagnosed with lung cancer and 158,000 people will die of the disease this year. The overall one-year survival rate for people with lung cancer is 44 percent, while the five-year rate is 17 percent.1
The majority of lung cancer patients – 85 to 90 percent – have non-small cell lung cancer. Evolving research has helped us to better understand the molecular makeup of these tumors, mutations in relevant genes and their effects on cancer cell proliferation and survival.2
Dr. Stephen Eck
Global Head of Oncology Medical Sciences